Overview of European pilot study of interferon  -1b in primary progressive multiple sclerosis

2004 ◽  
Vol 10 (1 suppl) ◽  
pp. S62-S64 ◽  
Author(s):  
X. Montalban
Keyword(s):  
Multiple Sclerosis ◽  
Pilot Study ◽  
Progressive Multiple Sclerosis ◽  
Primary Progressive Multiple Sclerosis ◽  
Primary Progressive

Overview of London trial of intramuscular interferon-b1a in primary-progressive multiple sclerosis

2004 ◽  
Vol 10 (3_suppl) ◽  
pp. S56-S57 ◽  
Author(s):  
David H Miller ◽  
Siobhan M Leary ◽  
Alan J Thompson
Keyword(s):  
Multiple Sclerosis ◽  
Pilot Study ◽  
Progressive Multiple Sclerosis ◽  
Primary Progressive Multiple Sclerosis ◽  
Primary Progressive ◽  
Patient Cohort ◽  
Quantitative Mr ◽  
Double Blinded ◽  
Clinical Measures ◽  
The Relationship

This short monograph describes the rationale, design and outcome of a pilot study of beta interferon in patients with primary progressive MS. A total of 50 patients were studied for 2 years using a randomized, double-blinded, placebo -controlled design. There was an emphasis on using MRI measures to evaluate outcome. The study showed that with the numbers studied, useful data could be obtained on safety and on efficacy on certain MRI measures. A larger study would be required to evaluate treatment on disability in this patient cohort and further work is needed to elucidate the relationship between quantitative MR and clinical measures over the longer term.

Overview of European pilot study of interferon b-1b in primary progressive multiple sclerosis

2004 ◽  
Vol 10 (3_suppl) ◽  
pp. S62-S64 ◽  
Author(s):  
Xavier Montalban
Keyword(s):  
Multiple Sclerosis ◽  
Pilot Study ◽  
Progressive Multiple Sclerosis ◽  
Lesion Volume ◽  
Primary Progressive Multiple Sclerosis ◽  
Primary Progressive

This short monograph describes a trial of interferon b-1b in patients with primary progressive multiple sclerosis (PPMS) or transitional MS. Designed as a randomized, placebo -controlled pilot, the trial randomly placed 73 eligible patients into two groups, placebo or interferon b-1b 8 MIU given subcutaneo usly every other day for two years. Significant differences favouring interferon b-1b in the MSFC score, T2 lesion volume and T1 lesion volume at 24 months were observed. Further study of interferon b-1b therapy in PPMS patients is warranted.

Sign in / Sign up

Export Citation Format

Share Document